Hypertrophic Cardiomyopathy Forecast In 26 Major Markets 2018-2028 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Aug 10, 2018--The “Hypertrophic Cardiomyopathy Forecast In 26 Major Markets 2018-2028” report has been added to ResearchAndMarkets.com’s offering.
Hypertrophic cardiomyopathy (HCM) is a disease that contains an autosomal dominant inheritance pattern and is a moderately common transmitted genetic disease. The disease, characterised by hypertrophy in the left ventricle, cannot be explained by the presence of other clinical symptoms, such as hypertension.
This report provides the current prevalent population for HCM across 26 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Norway, Sweden, Denmark, Austria, Switzerland, Ireland, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort.
Along with the current prevalence, the report provides an overview of the types, occlusion locations and the prevalence of associated disorders of HCM. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of HCM have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for HCM include:Chronic heart failure Angina pectoris Atrial fibrillation Tachycardia
Key Topics Covered:List Of Tables And Figures Introduction Cause Of The Disease Risk Factors & Prevention Diagnosis Of The Disease Variation By Geography/Ethnicity Disease Prognosis & Clinical Course Key Comorbid Conditions / Features Associated With The Disease Methodology For Quantification Of Patient Numbers Top-Line Prevalence For Hypertrophic Cardiomyopathy Features Of Hypertrophic Cardiomyopathy Patients Genetic Background Parameters And Symptoms Comorbidities Of Hypertrophic Cardiomyopathy Patients Abbreviations Used In The Report Other Publisher Services & Solutions Reports & Publications Online Epidemiology Databases Online Pharmaceutical Pricing Database References Appendix
For more information about this report visit https://www.researchandmarkets.com/research/k9p6k5/hypertrophic?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180810005101/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Cardiovascular Drugs
INDUSTRY KEYWORD: HEALTH CARDIOLOGY
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 08/10/2018 03:55 AM/DISC: 08/10/2018 03:55 AM